Jin Hee Kim1, Joo-Young Kim2, Mee Sun Yoon3, Young Seok Kim4, Jong Hoon Lee5, Hak Jae Kim6, Hunjung Kim7, Yeon-Joo Kim8, Chong Woo Yoo8, Byung-Ho Nam9, Tae Hyun Kim8, Suk-Ki Kim8, Sun Ho Kim8, Seokbom Kang8, Sang Soo Seo8, Myong Cheol Lim8, Sang-Yoon Park8. 1. Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea. 2. Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. Electronic address: jooyoungcasa@ncc.re.kr. 3. Department of Radiation Oncology, Chonnam National University, Hwasun Hospital, Republic of Korea. 4. Department of Radiation Oncology, Asan Medical Center, Unviersity of Ulsan, College of Medicine, Seoul, Republic of Korea. 5. Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University, Republic of Korea. 6. Department of Radiation Oncology, Seoul National University, College of Medicine, Republic of Korea. 7. Department of Radiation Oncology, Inha University Hospital, Inha University, School of Medicine, Incheon, Republic of Korea. 8. Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. 9. Cancer Control and Policy Department, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.
Abstract
BACKGROUND AND PURPOSE: The efficacy of prophylactic extended-field irradiation (EFI) plus concomitant cisplatin in patients with locally advanced uterine cervical cancer (LAUCC) is unknown, nor is it known whether tumor carbonic anhydrase IX (CA9) expression level, a hypoxia marker, influences survival outcome. MATERIAL AND METHODS: We recruited patients with UCC, FIGO stage IB1 with pelvic lymph node (LN) metastases to IVA with negative para-aortic LN on PET/CT. CA9 expression was examined and patients were randomized to either EFI or pelvic only radiotherapy (PRT) in each CA9 group. The primary outcomes were para-aortic recurrence-free survival (PARFS) and disease-free survival (DFS). RESULTS:Between 2006 and 2011, 79 patients with CA9-positive and 37 with CA9-negative tumors were enrolled, respectively. The median follow-up period was 69.2months (range 6.8-102.1). For CA9-positive patients, 5-year PARFS was 100% and 81.7% for those receiving EFI and PRT (p=0.007), respectively. DFS was 78.6% for EFI and 71.3% for PRT patients (p=0.353). For CA9-negative patients, 5y PARFS was 100% and 94.1% for EFI and PRT (p=0.317), respectively. DFS was 100% for EFI and 70.7% for PRT (p=0.018). CONCLUSION: EFI significantly reduced recurrences in PAN in patients with CA9-positive tumors, but survival outcome was not improved, due to high local recurrence and high distant metastases rates. This study indicates the necessity for new therapeutic strategies for LAUCC patients whose tumors show high CA9 expression.
RCT Entities:
BACKGROUND AND PURPOSE: The efficacy of prophylactic extended-field irradiation (EFI) plus concomitant cisplatin in patients with locally advanced uterine cervical cancer (LAUCC) is unknown, nor is it known whether tumorcarbonic anhydrase IX (CA9) expression level, a hypoxia marker, influences survival outcome. MATERIAL AND METHODS: We recruited patients with UCC, FIGO stage IB1 with pelvic lymph node (LN) metastases to IVA with negative para-aortic LN on PET/CT. CA9 expression was examined and patients were randomized to either EFI or pelvic only radiotherapy (PRT) in each CA9 group. The primary outcomes were para-aortic recurrence-free survival (PARFS) and disease-free survival (DFS). RESULTS: Between 2006 and 2011, 79 patients with CA9-positive and 37 with CA9-negative tumors were enrolled, respectively. The median follow-up period was 69.2months (range 6.8-102.1). For CA9-positive patients, 5-year PARFS was 100% and 81.7% for those receiving EFI and PRT (p=0.007), respectively. DFS was 78.6% for EFI and 71.3% for PRT patients (p=0.353). For CA9-negative patients, 5y PARFS was 100% and 94.1% for EFI and PRT (p=0.317), respectively. DFS was 100% for EFI and 70.7% for PRT (p=0.018). CONCLUSION: EFI significantly reduced recurrences in PAN in patients with CA9-positive tumors, but survival outcome was not improved, due to high local recurrence and high distant metastases rates. This study indicates the necessity for new therapeutic strategies for LAUCC patients whose tumors show high CA9 expression.
Authors: Leslie J H Bukkems; Ina M Jürgenliemk-Schulz; Femke van der Leij; Max Peters; Cornelis G Gerestein; Ronald P Zweemer; Peter S N van Rossum Journal: Clin Transl Radiat Oncol Date: 2022-05-30